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Abstract
Background: The Keap1-Nrf2 pathway has been reported to be impaired in several cancers. However, the status of
Keap1-Nrf2 system in human colorectal cancer (CRC) has not been elucidated.
Methods: We used colorectal cancer (CRC) cell lines and surgical specimens to investigate the methylation status
of the KEAP1 promoter region as well as expression of Nrf2 and its downstream antioxidative stress genes, NQO-1
and AKR1C1.
Results: DNA sequencing analysis indicated that all mutations detected were synonymous, with no amino acid
substitutions. We showed by bisulfite genomic sequencing and methylation-specific PCR that eight of 10 CRC cell
lines had hypermethylated CpG islands in the KEAP1 promoter region. HT29 cells with a hypermethylated KEAP1
promoter resulted in decreased mRNA and protein expression but unmethylated Colo320DM cells showed higher
expression levels. In addition, treatment with the DNA methyltransferase inhibitor 5-Aza-dC combined with the
histone deacetylase inhibitor trichostatin A (TSA) increased KEAP1 mRNA expression. These result suggested that
methylation of the KEAP1 promoter regulates its mRNA level. Time course analysis with the Nrf2-antioxidant
response element (ARE) pathway activator t-BHQ treatment showed a rapid response within 24 h. HT29 cells had
higher basal expression levels of NQO-1 and AKR1C1 mRNA than Colo320DM cells. Aberrant promoter methylation
of KEAP1 was detected in 53% of tumor tissues and 25% of normal mucosae from 40 surgical CRC specimens,
indicating that cancerous tissue showed increased methylation of the KEAP1 promoter region, conferring a
protective effect against cytotoxic anticancer drugs.
Conclusion: Hypermethylation of the KEAP1 promoter region suppressed its mRNA expression and increased
nuclear Nrf2 and downstream ARE gene expression in CRC cells and tissues.
Background
Colorectal cancer (CRC) is the second leading cause of
cancer-related deaths in most Western countries [1].
Over the past decade, molecular-targeted drugs have
been applied in combination with cytotoxic agents. Con-
sequently, the median overall survival for patients with
advanced CRC has become longer than 24 months.
Although the spectrum of therapeutic agents is becom-
ing broader, many issues remain to be solved regarding
cancer progression and acquisition of resistance to che-
motherapy in CRC.
The Kelch-like ECH-associated protein 1 (Keap1) and
nuclear factor-erythroid 2 -related factor 2 (Nrf2) path-
way is one of the master regulators of cellular defense
against oxidative and electrophilic stresses [2-4]. Nrf2 is
a basic region-leucine zipper (bZip)-type transcription
factor, which was identified as a binding protein of the
b-globin gene locus [5,6]. Subsequently, Nrf2 was recog-
nized to be a major transactivation factor for antioxidant
response element (ARE)-dependent gene transcription
[7]. The ARE is a cis-acting regulatory element of genes
encoding phase II detoxification enzymes and antioxi-
dant proteins, such as NAD(P)H quinone oxidoreduc-
tase-1 (NQO-1), glutathione S-transferases (GST), heme
oxygenase-1 (HO-1), and aldo-keto reductase family 1
member C1 (AKR1C1). Keap1 is a negative regulator of
Nrf2 and its main function is to serve as an adaptor for
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cullin3/ring box1 (Cul3/Rbx1) E3 ubiquitin ligase com-
plex [8-12]. Under physiological conditions, Keap1
maintains a low basal level of Nrf2 by constantly target-
ing Nrf2 for ubiquitin-mediated protein degradation
[13,14]. Once a cell is exposed to oxidative stress, Keap1
acts as a sensor and its cysteine residues are modified.
This modification prevents rapid degradation of Nrf2,
and the accumulated Nrf2 translocates into the nucleus,
leading to active transcription of downstream cytopro-
tective genes.
The Keap1-Nrf2 signaling pathway is impaired in lung
cancer, which is caused by mutations within functionally
important domains of the KEAP1 or NRF2 gene [15-17].
Impaired Keap1 activity and somatic mutation of Nrf2
lead to full Nrf2 activation, and cancer cells may acquire
a protective mechanism against the surrounding micro-
environment, resulting in cancer cell proliferation, dif-
ferentiation, and chemoresistance [15,17]. Similar
KEAP1 mutations have been reported in patients with
gall bladder cancer and in breast cancer cell lines
[18,19].
Recently, Wang et al. reported that the promoter
region of KEAP1 is aberrantly hypermethylated and
KEAP1 mRNA expression levels are low in some lung
cancer cell lines and lung cancer tissues [20]. Aberrant
methylation of the KEAP1 promoter region was also
reported in prostate cancer [21] and malignant glioma
[22]. However, the methylation status of KEAP1 in CRC
has not been elucidated.
As an impaired Keap1-Nrf2 system is induced by
mutation or hypermethylation in several types of human
cancer, we hypothesized that mutation or epigenetic
changes of KEAP1 may decrease Keap1 expression and
increase Nrf2 activity and transactivation of its down-
stream genes in CRC. In the present study, we investi-
gated the methylation status of KEAP1 in 10 CRC cell
lines and 40 surgically excised CRC tissue specimens.
We found frequent hypermethylation of the KEAP1
gene promoter region in human CRC. In addition, the
levels of Nrf2 target gene expression were upregulated
in hypermethylated cells.
Methods
CRC cell lines and patient tissue samples
Human CRC cell lines were obtained from cell banks.
The HT29 cell line was from American Type Culture
Collection, while WiDr, LoVo, DLD-1, SW837, and
Colo320DM cell lines were from the Human Science
Research Resources Bank (Osaka, Japan). HCT15 and
SW480 were from the Cell Resource Center for Biome-
dical Research Institute of Development, Aging, and
Cancer, Tohoku University. TT1TKB and CW-2 were
from RIKEN BioResource Center (Ibaraki, Japan). HT29,
WiDr, LoVo, DLD-1, SW480, and SW837 were cultured
in Dulbecco’s Modified Eagle’s Medium (DMEM) con-
taining 10% heat-inactivated fetal bovine serum (FBS).
HCT15, CW-2, and Colo320DM were cultured in
RPMI1640 medium containing 10% FBS. Forty CRC tis-
sues and adjacent normal colorectal tissue samples were
collected with written informed consent at Hirosaki
University Hospital. The tissues were immediately fro-
zen and stored at -80°C after surgical resection. The
study of CRC tissues samples was approved by the
Ethics Committee of Hirosaki University School of
Medicine.
Cell treatment
HT29 cells were plated at 5 × 106 cells/10-cm dish 24 h
prior to treatment. Cells were treated with 10 μM 5-aza-
2’-deoxycytidine (5-Aza-dC) for 96 h to block CpG
methylation, followed by treatment with 1 μM trichosta-
tin A (TSA), a reversible inhibitor of histone deacetylase,
for 24 h. To evaluate downstream gene expression of
Nrf2, HT29 and Colo320DM cells were treated with 50
μM tert-butylhydroquinone (t-BHQ), a potent inducer
of Nrf2-dependent gene expression, and cells were har-
vested at 2, 4, 8, 12, and 24 h after treatment. RNA was
then extracted, and real-time reverse transcription-poly-
merase chain reaction (RT-PCR) was performed as
described below to measure the expression of NQO1
and AKR1C1. The TaqMan Gene Expression Assay ID
for the NQO1 mRNA is Hs00168547_m1, and that for
AKR1C1 is Hs00413886_m1.
DNA and RNA extraction and DNA sequencing of the
KEAP1 gene
Genomic DNA was extracted from CRC cell lines using
a QIAmp DNA Mini kit (Qiagen, Valencia, CA), and
RNA was isolated using an RNeasy kit (Qiagen) accord-
ing to the manufacturer’s protocols. The DNA/RNA
concentration and their quality were evaluated by mea-
suring the ratio of optical density at 260/280 nm with
NanoDrop (NanoDrop Technologies Wilmington, DE).
For detection of KEAP1 mutation, DNA extracted from
cell lines was amplified using AmpliTaq Gold® Fast
PCR Master Mix (Applied Biosystems, Carlsbad, CA).
Direct sequencing was performed using the primer sets
reported previously by Shibata et al. [18].
Methylation-specific PCR (MSP) and bisulfite sequencing
PCR (BSP) of the KEAP1 gene
The primer sets of MSP and BSP used to target the
CpG islands located in the putative promoter region of
KEAP1 [20] are shown in Table 1 and Figure 1. These
primer sets were designed using Methyl Primer Express
Software v1.0 (Applied Biosystems), and PCR conditions
for MSP and BSP are shown in Table 1. Aliquots of 2
μg of extracted DNA from CRC cell lines were
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converted using an Epitect Bisulfite kit (Qiagen) in
accordance with the manufacturer’s instructions. Direct
DNA sequencing by dye terminator cycle sequencing
was performed after bisulfite treatment using an ABI
310 Genetic analyzer (Applied Biosystems). PCR amplifi-
cation with MSP primers was then performed using 10
μl of AmpliTaq Gold® Fast PCR Master Mix and 20 ng
of template DNA (the PCR conditions are shown in
Table 1). CpG-methylated HeLa genomic DNA and 5-
Aza-dC-treated Jurkat genomic DNA (New England
Biolabs Japan, Tokyo, Japan) were used as controls for
methylated and unmethylated sequence detection,
respectively. MSP products were analyzed by 2% agarose
gel electrophoresis, stained with ethidium bromide, and
visualized with a UV transilluminator.
Real-time RT-PCR
Expression of KEAP1 mRNA was measured by quantita-
tive real-time PCR in triplicate using TaqMan Gene
Expression Assays (Applied Biosystems) in the ABI
PRISM 7000 sequence detection system (Applied Biosys-
tems). Intact total RNA was extracted as described
above. Reverse transcriptase reactions were performed
on aliquots of 2 μg of total RNA using a High Capacity
cDNA Reverse Transcription kit (Applied Biosystems)
according to the manufacturer’s protocol. The






Initial denaturation at 95°C (10 min) and 35 cycles at 95°C (3 s), 52°C (3 s), 72°C (5 s), and a final extension at 72°C (10
s)




Initial denaturation at 95°C (10 min) and annealing temperature decrement of 0.5°C every cycle (from 70°C to 66.5°C)







Initial denaturation at 95°C (10 min) and annealing temperature decrement of 0.5°C every cycle (from 64°C to 60.5°C)
followed by 32 cycles of 60°C(3 s), 72°C (5 s), and a final extension at 72°C (10 s)
Figure 1 Positions of methylation-specific PCR (MSP) and bisulfite sequencing PCR (BSP) primers. BSP primers (-254 to -153) were
designed to include the 12 CpG sites. MSP forward and reverse primers contained two and three CpG sites, respectively.
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conditions for reverse transcription were 25°C (10 min),
37°C (120 min), and 85°C (5 min). The TaqMan Gene
Expression Assay ID of the KEAP1 mRNA is
Hs00202227_m1. Calculations were performed using the
comparative CT method. GAPDH (Assay ID
Hs99999905_m1) was used as an endogenous control
gene for normalization of PCR for the amount of RNA
added to the reverse transcription reactions. The mRNA
levels are expressed as fold induction relative to the
control. The conditions for real-time PCR were 50°C (2
min), 95°C (10 min), followed by 40 cycles of 95°C (15
s) and 60°C (1 min).
Western blotting analysis
Whole-cell, cytoplasmic, and nuclear extracts from
HT29 and Colo320DM cells were prepared using a
Nuclear Extract kit (Active Motif, Tokyo, Japan) accord-
ing to the manufacturer’s instructions. The protein con-
centration was determined using a Pierce BCA Protein
Assay Kit (Thermo Scientific, Waltham, MA). Whole-
cell lysates containing 5 μg of protein from HT29 cells
and 12.5 μg of protein from Colo320DM cells were
loaded in each lane, run on a NuPAGE 4%-12% Bis-Tris
gel (Invitrogen, Carlsbad, CA), and transferred onto
PVDF iBlot Gel Transfer Stacks (Invitrogen). After blot-
ting, membranes were blocked in Tris-buffered saline
containing 0.05% Tween-20 (TBS-T) and 1% non-fat
dried milk for 1 h. After blocking, membranes were
probed overnight at 4°C with a rat monoclonal antibody
against Keap1 (dilution 1:5,000; clone#144), a rabbit
polyclonal antibody against Nrf2 (1:200; Santa Cruz,
#sc-722), a mouse monoclonal antibody against NQO-1
(1:1,000; Santa Cruz Biotechnology, #sc-32793), and a
mouse monoclonal antibody against AKR1C1 (1:1,000;
ATGen,#ATGA0201). Membranes were washed four
times (10 min per wash) with antibody dilution buffer
and then incubated with goat anti-rabbit IgG (1:2,000;
Santa Cruz Biotechnology) for 1 h at room temperature.
A rabbit monoclonal antibody against b-actin (1:2,000;
Cell Signaling Technologies, Danvers, MA) and a mouse
monoclonal Antibody against histone H1 (1:500; Santa
Cruz Biotechnology, #sc-8030) were used as controls.
After extensive washing (4 × 10 min with TBS-T), anti-
body detection was performed with SuperSignal West
Pico Chemiluminescent Substrate Kits (Pierce, Rockford,
IL).
Statistical analysis
Data are presented as the means ± standard deviation.
Student’s t test was used to assess the significance of
three independent experiments. In all analyses, P < 0.05
was taken to indicate statistical significance.
Results
Genetic alteration of KEAP1 in CRC cell lines
As KEAP1 gene mutations have been reported in other
types of human cancer, we sequenced all protein-coding
exons in 10 CRC cell lines. We detected a C-to-T tran-
sition (G157G) in exon 2 of LoVo cells, a C-to-G transi-
tion (L470L) in exon 4 of LoVo, DLD-1, TT1TKB,
HCT15, and CW-2 cells, and a C-to-T transition
(Y537Y) in exon 5 of CW-2 cells. All mutations were
single-nucleotide polymorphisms and had been reported
previously. No missense or nonsense mutations were
observed.
Analysis of the methylation status of the KEAP1 promoter
region in 10 CRC cell lines
The KEAP1 promoter region was hypermethylated in
lung cancer cell lines and lung cancer tissues, as
reported previously by Wang et al. [20]. They reported
that the P1 region, including 12 CpGs (-291 to -89), was
heavily hypermethylated in the CpG islands around the
transcriptional initiation site of KEAP1. Therefore, we
investigated the methylation status of the P1 region in
KEAP1 using MSP and BSP primers designed as shown
in Figure 1. MSP analysis indicated that the P1 region
was hypermethylated in HT29, WiDr, LoVo, DLD-1,
SW480, TT1TKB, HCT15, and CW-2 cells, but not in
SW837 or Colo320DM (Figure 2A). Furthermore, we
determined the methylation status of each of the 12
CpG dinucleotide sites in the P1 region by BSP. As
shown in Figure 2B, most of CpG sites were methylated
in HT29, WiDr, LoVo, DLD-1, SW480, TT1TKB,
HCT15, and CW-2, but not in SW837 or Colo320DM.
Representative results of methylation analysis of CpG
islands in the promoter region of the KEAP1 gene are
shown in Figure 2B. All cytosines in the P1 region were
converted to thymidine in Colo320DM cells, although in
HT29 cells the 5’-methylcytosines of CpG sites
remained as cytosines. In contrast, both cytosines and
thymidines in the 5’-methylcytosines of CpG sites were
observed in HCT15 cells. Aberrant hypermethylation in
the KEAP1 promoter region was frequently observed in
human CRC cell lines.
Association between KEAP1 methylation and KEAP1
mRNA expression
To examine the effects of KEAP1 methylation on its
mRNA expression level, we performed real-time RT-
PCR of KEAP1 mRNA as shown in Figure 3A. Cell lines
with methylated KEAP1 (HT29, WiDr, LoVo, DLD-1,
SW480, TT1TKB, HCT15, and CW-2) exhibited lower
levels of KEAP1 mRNA expression compared with the
unmethylated cell lines SW837 and Colo320DM.
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To determine whether expression of KEAP1 mRNA is
epigenetically downregulated, expression of KEAP1
mRNA was measured after treatment with the demethylat-
ing agent 5-Aza-dC at 10 μM for 4 days and/or the rever-
sible histone deacetylase inhibitor TSA at 1 μM for 24 h in
HT29 cells. The expression of KEAP1 mRNA was mark-
edly increased after 5-Aza-dC and TSA treatment in the
methylated cell line HT29, but no changes were observed
in KEAP1 mRNA expression level in the unmethylated
cell line Colo320DM (Figure 3B). MSP analysis showed
that methylation of the keap1 promoter in HT29 cells was
reversed after 5-Aza-dC and TSA treatment (Figure 3B).
These observations suggest that epigenetic alterations reg-
ulate Keap1 expression in CRC cell lines.
Protein levels of Keap1 and Nrf2
To further examine whether Keap1 protein levels are
different between methylated and unmethylated cells,
we performed Western blotting analysis. The Keap1
protein level was reduced in HT29 cells, compared with
that in Colo320DM cells, as shown in Figure 3C (left).
Keap1 protein expression in the methylated cell line
HT29 was reversed by treatment with 5-Aza-dC and
TSA, but was unchanged in the unmethylated cell line
Colo320DM (Figure 4C), mirroring similar changes in
KEAP1 mRNA expression. In addition, Nrf2 protein
clearly accumulated in the nuclear fraction of HT29
cells, as compared to its level in Colo320DM, whereas
Nrf2 protein levels in cytoplasmic fractions were equiva-
lent in these two cell lines (Figure 3C, right). Nrf2 pro-
tein accumulation in HT29 cells was reduced by
demethylation (Figure 4C).
NQO1 and AKR1C1 mRNA and protein levels
We measured NQO1 and AKR1C1 mRNA levels at dif-
ferent time points after treatment with t-BHQ, an acti-
vator of the Nrf2-ARE pathway, at a concentration
of100 μM. NQO1 and AKR1C1 expression levels were
higher in the methylated cell line HT29 than in the
unmethylated cell line Colo320DM without stimulation
(Figures 4A and 4B left). Furthermore, t-BHQ treatment
significantly increased NQO-1 and AKR1C1 mRNA
levels in HT29 cells. AKR1C1 mRNA was below the
limit of detection both at baseline and after stimulation
in Colo320DM cells. The expression of NQO1 and
AKR1C1 mRNA in the methylated cell line HT29 was
reversed after treatment with 5-Aza-dC and TSA (Fig-
ures 4A and 4B (right)). NQO-1 and AKR1C1 proteins
were overexpressed in methylated HT 29 cells, but their
levels were reduced after demethylation (Figure 4C).
Figure 2 Analysis of KEAP1 promoter region methylation status in CRC cell lines. (A) Results of MSP in 10 CRC cell lines. (B) Results of BSP.
Representative methylation analysis of CpG islands at the promoter region of the KEAP1 gene (upper). Methylation is indicated in red.
Methylation status of each of the 12 CpG sites in 10 CRC cell lines (lower). Black circles represent methylated CpGs. White circles represent
unmethylated CpGs.
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Detection of KEAP1 methylation using MSP in surgical
samples and association between methylation status and
clinicopathological features in CRC
The methylation status of each sample was confirmed
by MSP and BSP. Representative MSP products for
KEAP1 in tumor tissues and normal tissues are shown
in Figure 5A. Representative results of MSP sequence
analysis of tumor tissues are presented in Figure 5B.
Aberrant promoter methylation of KEAP1 was detected
in 21/40 (53%) tumor tissues and 10/40 (25%) normal
Figure 3 KEAP1 and Nrf2 expression. (A) KEAP1 mRNA expression in 10 CRC cell lines was evaluated by real-time PCR. The expression level in
Colo320DM cells was arbitrarily designated as 1. Columns, mean (n = 3); bars, standard deviation (SD). (B, upper) KEAP1 mRNA levels in HT29
cells (methylated) and Colo320DM cells (unmethylated) were analyzed by real-time PCR after treatment with 5-Aza-dC, TSA, and 5-Aza-dC + TSA.
The expression level in HT29 cells was arbitrarily designated as 1. Columns, mean (n = 3); bars, SD. *P < 0.05. (B, lower) MSP analysis of in HT29
cells and Colo320DM treated with 5-Aza-dC + TSA. M, methylation-specific primer; U, non-methylation-specific primer. (C) Western blot analysis
of Keap1 and Nrf2 in methylated and unmethylated colon cancer cells. Whole-cell extracts (W), cytosolic extracts (C), and nuclear extracts (N)
were prepared from Colo320DM and HT29 cells. Extracts were stained with antibody to Keap1 or Nrf2A. b-Actin, histone H1, and GAPDH
antibodies were used as loading controls for whole-cell, cytosolic, and nuclear fractions, respectively.
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mucosal specimens (Table 2). Compared with normal
mucosa, the methylation of KEAP1 was more promi-
nent in tumor tissues (P = 0.001). We performed sta-
tistical analyses to determine whether the KEAP1
methylation status of colorectal tumor samples is
associated with the clinicopathological features of CRC
patients. In the tumor tissues, methylation of KEAP1
was not associated with any clinicopathological fea-
tures, such as primary site location, differentiation,
gender, Duke’s stage, clinical stage, age, lymph node
Figure 4 Expression of the Nrf2 target genes NQO-1 and AKR1C1 after t-BHQ treatment. Real-time PCR analysis of the Nrf2 target genes
NQO-1 (A, left) and AKRC1 (B, left) in HT29 cells (methylated) and Colo320DM cells (unmethylated). Cells were treated with the Keap1 stimulator
t-BHQ for 24 h. Columns, mean (n = 3); bars, SD. *P < 0.05. Real-time PCR analysis of NQO-1 (A, right) and AKRC1 (B, right) in HT29 cells treated
with 5-Aza-dC + TSA and then t-BHQ (for 12 h). Keap1 protein levels (C, upper), protein expression of downstream ARE genes (C, upper), and
changes in the subcellular distribution of Nrf2 protein (C, lower) after 5-Aza-dC and TSA treatment. Cells were treated with 5-Aza-dC and TSA.
Expression levels of each protein were determined by Western blotting. b-actin and histone H1 were used as loading controls.
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metastasis, and serum concentration of carcinoembryo-
nic antigen (CEA) (data not shown). Additionally, we
analyzed methylated HT29 cells and tumor samples by
immunohistochemistry using an anti-human Nrf2
antibody. As shown in Figure 5C, strong expression of
Nrf2 protein was detected in the nuclei of HT29 cells
and in a methylated tissue sample. This observation
indicates that promoter methylation of the KEAP1
Figure 5 Methylation of the KEAP1 promoter in CRC tissue samples. (A) MSP for the KEAP1 promoter was performed using bisulfite-
modified DNA from 40 CRC tissues and adjacent normal colorectal tissues. MSP results from 10 patients are shown. M: MSP of methylation-
specific primers; U: MSP of non-methylation-specific primers; P: positive methylated DNA control; N: negative unmethylated DNA control. (B)
Representative results of MSP sequence analysis of tumor tissues. The methylation status of the KEAP1 promoter region in patient tumor tissues
was determined using methylation-specific primers (upper), and non-methylation-specific primers (lower). Methylation is indicated in red. (C)
Expression and subcellular localization of Nrf2. Nrf2 was more highly expressed in HT29 cells (a) and a methylated tissue sample (c) compared
with Colo320 cells (b) and a non-methylated tissue sample (d). Expression and localization of Nrf2 was studied using an anti-human Nrf2
antibody.
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gene enables Nrf2 to translocate from the cytoplasm to
the nucleus.
Discussion and conclusions
We found frequent hypermethylation of the KEAP1 pro-
moter region in human CRC cell lines. This hyper-
methylation of KEAP1 resulted in reductions in KEAP1
mRNA and protein expression, upregulation of Nrf2
activity, and thus overexpression of downstream genes,
such as NQO-1 and AKR1C1. We also observed aberrant
methylation of KEAP1 in human CRC tissues. This is
the first report discussing activation of Keap1/Nrf2 sig-
naling by KEAP1 hypermethylation in CRC.
Loss of Keap1 function has been reported associated
with KEAP1 gene mutations in tumor tissue samples
from lung, gall bladder, breast, and prostate cancer
[15,18,19,21]. We found only synonymous mutations
consisting of a C-to-T transition with G157G in exon 2,
a T-to-C transition of L471L in the DGR4 domain, and
a C-to-T transition with Y537Y in the DGR5 domain in
CRC cell lines. However, these mutations were single-
nucleotide polymorphisms. Frequent KEAP1 gene muta-
tions were reported in human non-small cell lung can-
cer (NSCLC) [15]. All mutations were within highly
conserved amino acid residues located in the Kelch or
intervening region domain of the Keap1 protein, sug-
gesting that these mutations were likely to abolish
Keap1 repressor activity against Nrf2. In addition, C23Y
mutation in the N-terminal domain of Keap1 has been
reported to have impaired ability to repress Nrf2 activity
due to its inability to stimulate the ubiquitylation and
degradation of Nrf2 in breast cancer [19]. A C-to-T
transition with T314M and a T-to-C transition with
Y255H were detected in six prostatic cancer cell lines
[21]. Shibata et al. also reported mutations of KEAP1 in
biliary tract cancer tissue [18]. These changes are in the
central intervening region of Keap1 and alter highly
conserved amino acids.
Another mechanism of impaired Keap1 activity is
hypermethylation of KEAP1. We found that 8 of 10
CRC cell lines had methylated CpG islands in the pro-
moter region of the KEAP1 gene where methylation was
found in other types of cancer [20,22,23]. Hypermethyla-
tion of KEAP1 resulted in decreased mRNA expression,
which was confirmed by the increase in KEAP1 mRNA
expression by combined treatment with the DNA
methyltransferase inhibitor 5-Aza-dC and the histone
deacetylase inhibitor TSA (Figure 4C). Hypermethylation
of KEAP1 caused final stimulation of Nrf2 target genes.
However, the reason for the expression of KEAP1
mRNA being lower in unmethylated SW837 cells than
in methylated HCT15 cells is unknown. Wang et al.
investigated three lung cancer cell lines and five tumor
samples, and found frequent hypermethylation of the
CpG islands in the promoter region of KEAP1 and
reduced levels of KEAP1 mRNA expression. In contrast,
a normal bronchial cell line had clearly less methylation
of the KEAP1 promoter region and elevated mRNA
expression [20]. Hypermethylation of KEAP1 found in
prostate cancer also stimulated the Nrf2 signal [21].
Biological effects of constitutive Nrf2 activation by
Keap1 dysfunction due to mutations or low-level expres-
sion by hypermethylation have been reported previously
[18,23,24]. Constitutive expression of the cytoprotective
gene by Nrf2 activation in lung cancer cells led to che-
motherapy resistance [23]. Nrf2 activation also stimu-
lated growth of lung cancer cells. Nrf2 activation by
KEAP1 mutation or hypermethylation of promoter CpG
islands causes radioresistance and promotes tumor
growth in prostatic cancer [21]. In the present study, we
observed accumulation of Nrf2 protein in the nuclei in
methylated HT29 cells, and overexpression of phase II
detoxifying enzymes NQO-1 and AKR1C1 both at base-
line and after t-BHQ stimulation. These reports indicate
that KEAP1 functions as a tumor suppressor gene in
human tumors. Although we did not evaluate the biolo-
gical effects of activated Nrf2, we assume that CRC cells
with KEAP1 gene hypermethylation may be resistant to
chemotherapeutic agents and show upregulated cell
growth, as reported in other types of cancer.
There have been only two previous reports regarding
Keap1/Nrf2 l in CRC cells [24,25]. Activation of the
Keap1/Nrf2 signaling pathway mediates protective
responses to mitigate nitric oxide (NO)-induced damage
and may contribute to the resistance of CRC cells to
NO-induced cytotoxicity [24]. Arlt et al. reported that
Nrf2 activity is elevated in colon cancer, accounting for
overexpression of the proteasome subunit proteins and
thus for increased proteasome activity [25]. Conversely,
small interfering RNA-mediated Nrf2 knockdown
decreased their expression and reduced proteasome
activity, thus indicating that Nrf2 is related to colorectal
carcinogenesis. This Nrf2 activation may be due to the
low level of Keap1 expression due to hypermethylation,
as found in the present study.
Biological effects that activate Nrf2 signaling prompted
us to study the relationship between the status of
Keap1/Nrf2 signaling and clinicopathological features of
the tumors. Type II endometrial cancer, which is mostly
Table 2 KEAP1 promoter methylation frequency in
colorectal cancer and adjacent normal mucosa
Methylation status
Variable N Present Absent
Tumor tissue 40 21 (53%) 19 (47%)
Adjacent normal mucosa 40 10 (25%) 30 (75%)
P < 0.05
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malignant and is associated with a poor prognosis
among gynecological malignancies, shows elevated Nrf2
protein expression, whereas benign tumors and type I
endometrial cancer do not [26]. On immunohistochem-
ical analysis of human NSCLC, increased Nrf2 expres-
sion and low or absent Keap1 expression were
associated with worse survival [27]. In contrast, the
prognosis of malignant glioma was better among
patients with than among those without a methylated
KEAP1 promoter region [22]. Although we did not
investigate the prognosis of patients with CRC, further
studies are needed to understand the role of Keap1/Nrf2
signaling in human CRC.
In conclusion, the results of the present study revealed
hypermethylation of the KEAP1 promoter region in
human CRC, leading to downregulation of KEAP1
mRNA expression, thus activating Nrf2 and expression
of its downstream target genes. Cancerous tissues exhib-
ited more frequent methylation of KEAP1 than normal
tissue in surgically resected CRC specimens.
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